Challenges in targeting KRASG12C mutations

Adrian Sacher, MD, Princess Margaret Cancer Centre, Toronto, Canada, talks on the challenges in targeting KRADG12C. A predominant challenge faced is that compared to other drugs, such as tyrosine kinase inhibitors (TKIs), current response rates with KRASG12C inhibitors are limited. In regard to the novel KRASG12C inhibitor, GDC-6036, combination strategies are under development to optimize clinical efficacy whilst maintaining safety and tolerability. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.